

Driving growth in biomaterials innovation

Johanna Hagelberg

Executive Vice President Biomaterials



Disclaimer



It should be noted that Stora Enso and its business are exposed to various risks and uncertainties and certain statements herein which are not historical facts, including, without limitation those regarding expectations for market growth and developments; expectations for growth and profitability; and statements preceded by "believes", "expects", "anticipates", "foresees", or similar expressions, are forward-looking statements. Since these statements are based on current plans, estimates and projections, they involve risks and uncertainties which may cause actual results to materially differ from those expressed in such forward-looking statements. Such factors include, but are not limited to: (1) operating factors such as continued success of manufacturing activities and the achievement of efficiencies therein, continued success of product development, acceptance of new products or services by the group's targeted customers, success of the existing and future collaboration arrangements, changes in business strategy or development plans or targets, changes in the degree of protection created by the group's patents and other intellectual property rights, the availability of capital on acceptable terms; (2) industry conditions, such as strength of product demand, intensity of competition, prevailing and future global market prices for the group's products and the pricing pressures thereto, price fluctuations in raw materials, financial condition of the customers and the competitors of the group, the potential introduction of competing products and technologies by competitors; and (3) general economic conditions, such as rates of economic growth in the group's principal geographic markets or fluctuations in exchange and interest rates. All statements are based on management's best assumptions and beliefs in light of the information currently available to it and Stora Enso assumes no obligation to publicly update or revise any forward-looking statement except to the extent legally required.

13 September 2022 THE RENEWABLE MATERIALS COMPANY



Lignin makes up 1/3 of a tree with a world of possibilities



Cellulose 1/3

Lignin 1/3

Hemicellulose 1/3



Biomaterials production site



Biochemicals Green energy



Our products and sales mix form the foundation for biomaterial innovation















Innovative biomaterials






Leading edge research with worldwide reach





Strong financial performance in Biomaterials





Significant growth opportunity in biomaterials innovation



Market size	€10 billion	€20 billion
Long-term EBITDA margin potential	50%	40%
CAGR	+ -	
	Anode material +25-30% CAGR	Bio-binders +3-4% CAGR

Reducing carbon footprint with bio-based binders



High bonding strength and water resistance

Replacing fossil-based chemicals

Market €20 billion Current share <1%






Electrification is great

But batteries still rely on fossil-based materials

European anode demand is estimated to be 1 million tonnes by 2030

Lignode replaces non-renewable graphite in batteries





Stationary energy storage

Other electric products

Higher performance and faster charging compared to pure graphite



Properties	100% Lignode	Lignode/graphite mixtures
Fast charging/ discharging	+ + +	+ +
Low temperature performance	+ + +	+ +
Cycling stability	+ + +	+ +
Energy density	- +	
Sustainability	+ + +	+



Accelerating the development and scale-up with customers and partners





Biomaterials ~2030 ambition



€1bn sales in innovative biomaterials

Full scale-up of Lignode

50% carbon footprint reduction

Reduced market pulp position

Leadership in European fluff

Maintaining strong competitiveness













THE RENEWABLE MATERIALS COMPANY